Loading clinical trials...
Loading clinical trials...
Phase 1 Single Centre, Double-blind, Randomized, Placebo-controlled, Dose-escalation Study of Plant-based H5 VLP (Virus-like Particles), (H5N1) Pandemic Influenza Vaccine Adjuvanted With Aluminium Hydroxide and Administered to Healthy Adults 18-60 Years of Age
Conditions
Interventions
H5 VLP pandemic influenza vaccine 5 µg
H5 VLP pandemic influenza vaccine 10 µg
+2 more
Locations
1
Canada
MUHC Vaccine Study Centre
Pierrefonds, Quebec, Canada
Start Date
September 1, 2009
Primary Completion Date
December 1, 2009
Completion Date
July 1, 2010
Last Updated
November 4, 2010
NCT05907564
NCT04657120
NCT04170348
NCT05622942
NCT05592431
NCT06113757
Lead Sponsor
Medicago
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions